Last updated: July 30, 2026
Gadofosveset trisodium (Vasovist) is an MRI blood-pool contrast agent whose commercial trajectory has been shaped by limited market adoption, competitive pressure from gadolinium-based alternatives, and regulatory/label changes in multiple regions. No current phase 3 program or late-stage registrational study is clearly attributable to a definable, active development cycle that would support a near-term re-launch thesis.
What is the current clinical trials status for gadofosveset trisodium?
Featured snippet answer: Gadofosveset trisodium’s clinical pipeline is not showing a clearly active, late-stage (phase 3) registrational program as of recent public trial registry snapshots. Earlier development was driven by cardiovascular MRI indications and next-generation blood-pool imaging use cases.
Are there any active phase 3 clinical trials for gadofosveset trisodium?
No clearly identifiable active phase 3 trials are associated with gadofosveset trisodium that would imply imminent market expansion or re-submission.
What phase 2 or investigator-initiated studies remain relevant?
Publicly indexed studies historically focused on:
- Cardiovascular MRI for perfusion, angiography, and blood-pool characterization
- Diagnostic performance comparisons versus conventional gadolinium agents
- Imaging protocol optimization (timing, dosing, sequences)
What evidence base supports current use?
Gadofosveset’s differentiation came from prolonged intravascular residence time enabling higher-quality vascular imaging windows. That profile is directly targeted by the clinical endpoints in its cardiovascular MRI program, but the market has shifted toward broader “good enough” contrast options and workflow simplicity.
What is the Orange Book status of gadofosveset trisodium, and does it affect generic or biosimilar entry?
Featured snippet answer: Gadofosveset trisodium is not a biologic and does not have an Orange Book “biosimilar” framework. Commercial entry is instead governed by small-molecule patent and exclusivity posture and by any remaining regulatory exclusivity or labeling protection.
How does small-molecule exclusivity typically influence entry?
For contrast agents, market access risk tends to come from:
- Patent protection on composition, salts, and formulations
- Patents on manufacturing processes
- Patent protection on specific imaging methods and dosing regimens
- Regulatory data exclusivity and any transferable rights, depending on jurisdiction
What matters for investors and litigators?
The practical question is not biosimilarity risk but:
- Whether brand supply is sustained in key markets
- Whether generics can clear regulatory requirements for the same active substance and dosage form
- Whether the label includes protected method claims that constrain “true equivalence”
What patents protect gadofosveset trisodium, and when do they expire?
Featured snippet answer: Gadofosveset trisodium’s patent estate is largely a legacy portfolio tied to the original development. The remaining enforceable landscape typically covers formulation and manufacturing, with method-of-use protection depending on jurisdiction.
Patent estate components that historically cover contrast agents
- Chemical composition claims (gadofosveset trisodium and related salts)
- Formulation claims (buffers, stability, and excipient packages)
- Manufacturing/process claims (steps that control purity and particle/chelator stability)
- Indication-specific claims (cardiovascular imaging windows and sequences)
How to project the generic entry window from a patent-practice perspective
For a legacy contrast agent, generic or authorized-supplier entry can be constrained for years by:
- Remaining formulation/process patents
- Labeling position (whether competitors can reference the same clinical/quality package)
- Tender specifications in hospitals and regional procurement
What is the regulatory status of gadofosveset trisodium today?
Featured snippet answer: Gadofosveset trisodium is/was authorized as an MRI contrast agent under brand naming such as Vasovist in some markets. Its availability has been inconsistent across regions.
How regulatory status affects market size
Contrast agents trade on:
- Tender and hospital formularies
- Radiology department workflow compatibility
- Supply reliability
- Reimbursement policy
Even when regulatory approval exists, commercial scale can stay limited if hospitals switch to alternative gadolinium agents with simpler logistics or stronger pricing leverage.
How big is the gadofosveset trisodium market, and where is demand concentrated?
Featured snippet answer: The market is best described as niche within contrast-enhanced MRI, with demand concentrated in cardiovascular MRI and imaging centers that adopt blood-pool agent protocols.
Market drivers that support demand
- Cardiovascular imaging needs where intravascular persistence improves image timing
- Protocols optimized for vascular delineation
- Clinical preferences in select sites
Market headwinds that compress demand
- Broad adoption of alternative gadolinium-based contrast agents
- Competitive pricing and tender pressure
- Shifts in imaging protocols as newer products and general-purpose agents dominate routine work
- Safety concerns broadly affecting the gadolinium class, influencing prescribing patterns and selection
Commercial distribution structure
Historically, contrast agent demand is concentrated by:
- Hospital procurement cycles
- Radiology unit preferences
- National reimbursement rules and tender bundling
What do clinical trial updates imply for future adoption?
Featured snippet answer: Without a current active late-stage development cycle, trial “updates” translate more into evidence retention than into a new commercial inflection. Adoption is therefore driven by competitive differentiation and procurement behavior rather than by imminent label expansion.
How trial outcomes typically map to commercial adoption for blood-pool agents
For this class, adoption depends on:
- Demonstrated incremental diagnostic value in target protocols
- Clear workflow advantages (shorter scanning times, improved reproducibility)
- Ease of dosing and availability in routine practice
- Stable supply and predictable reimbursement
What is the competitive landscape for gadofosveset trisodium?
Featured snippet answer: The competitive set is other gadolinium-based MRI contrast agents used for vascular and cardiovascular MRI. Blood-pool differentiation is the main historical value proposition, but competitors can win on breadth of use, pricing, and ease of administration.
Key competitive axes
- Blood-pool duration versus conventional extracellular agents
- Safety labeling and risk management requirements
- Tender pricing and procurement volume
- Indication breadth and radiology guideline alignment
Competitive outcomes to expect in procurement
Even when a blood-pool agent performs well, purchasing decisions frequently favor:
- Agents with the broadest utilization across MRI protocols
- Lower acquisition cost
- Fewer operational constraints in busy imaging centers
What market projection scenarios apply to gadofosveset trisodium?
Featured snippet answer: Near-term projections are dominated by supply continuation and procurement cycles rather than by incremental clinical growth. A realistic projection range assumes flat-to-declining revenue absent label expansion, with upside only if supply and reimbursement align in major markets.
Base case (most likely): flat-to-decline
Assumptions:
- No new phase 3 label expansion
- Continued competitive pressure from broader-use gadolinium agents
- Limited penetration beyond established cardiovascular imaging centers
- Gradual erosion through tender switching
Upside case: stabilization via targeted lifecycle management
Assumptions:
- Re-affirmation of value in specific cardiovascular protocols
- Stable supply and predictable tender pricing
- Contract wins in regional radiology networks
Downside case: exit or further supply constraints
Assumptions:
- Supply disruptions or withdrawal in key regions
- Continued tender consolidation toward competitor SKUs
- Reimbursement changes reducing contrast agent demand or shifting to alternatives
How should revenue and volume be modeled for investment or licensing decisions?
Featured snippet answer: Model volume using hospital tender penetration and retention rather than assuming new patient demand growth. Revenue sensitivity is highest to procurement pricing and supply stability.
Practical model structure for contrast agents
- Step 1: Estimate addressable cardiovascular MRI volume per region
- Step 2: Estimate penetration of blood-pool protocols among contrast-enhanced MRIs
- Step 3: Apply retention based on tender cycles (multi-year)
- Step 4: Apply price erosion assumptions based on competitor pricing and tender bundling
- Step 5: Apply supply risk adjustment (probability-weighted availability)
What drives variance most
- Tender pricing and contract duration
- Competitive switching after price resets
- Hospital formulary changes after guideline updates
- Regulatory availability status and distribution coverage
What licensing or partnerships would matter for gadofosveset trisodium?
Featured snippet answer: Any monetization pathway is likely through supply agreements, authorized generics, or regional distribution partnerships that lock in tender volume and stabilize pricing.
Partnership targets
- Major MRI imaging networks and radiology conglomerates
- Regional distributors with tender execution capability
- Authorized generic manufacturers if regulatory and patent conditions permit
What to watch in deal mechanics
- Minimum purchase commitments
- Pricing floors linked to input costs
- Supply and quality SLAs
- Label use constraints (indication and dosing language)
When does gadofosveset trisodium lose exclusivity in key markets?
Featured snippet answer: For a legacy small-molecule contrast agent, exclusivity timing is determined by the last expiring patents covering composition/formulation and the expiration or survival of regulatory exclusivity tied to initial approvals.
How to interpret “loss of exclusivity” for this product class
Even after patent expiry, commercial launch by competitors can be delayed by:
- Regulatory process requirements for the same dosage form
- Quality dossier readiness and stability data
- Label compatibility
- Hospital tender lead times
Key Takeaways
- Gadofosveset trisodium’s commercial future is constrained by niche adoption and competitive pressure from broader-use gadolinium MRI contrast agents.
- Public clinical trial activity does not indicate a clear, active late-stage registrational program that would justify an imminent label-driven growth reset.
- Market projections are dominated by tender penetration, reimbursement, and supply stability rather than by new clinical efficacy signals.
- The practical “value” of the asset is tied to lifecycle supply and distribution execution, plus any remaining patent/formulation constraints that govern time-to-competitor availability.
FAQs
1) Is gadofosveset trisodium still used in cardiovascular MRI today?
It is used in selected settings where blood-pool contrast timing improves vascular imaging workflow and where procurement supports continued access.
2) What is the main clinical advantage of gadofosveset trisodium versus extracellular gadolinium agents?
Its intravascular persistence enables longer imaging windows for blood-pool vascular characterization in cardiovascular MRI protocols.
3) Can generics enter gadofosveset trisodium after patent expiry?
In principle, yes, but real-world entry is constrained by formulation/process patent coverage, regulatory dossier requirements, and hospital tender/label compatibility.
4) Are there biosimilar risks for gadofosveset trisodium?
No. It is a small-molecule MRI contrast agent, not a biologic product.
5) What drives price erosion for MRI contrast agents like gadofosveset trisodium?
Tender bundling, competitor pricing, and formulary consolidation toward high-volume, broad-utility products.
References (APA)
- ClinicalTrials.gov. (n.d.). Search results for gadofosveset trisodium. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA database search: gadofosveset trisodium. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
